These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Hemolytic uremic syndrome with dual caution in an infant: cobalamin C defect and complement dysregulation successfully treated with eculizumab. Barlas UK; Kıhtır HS; Goknar N; Ersoy M; Akcay N; Sevketoglu E Pediatr Nephrol; 2018 Jun; 33(6):1093-1096. PubMed ID: 29558000 [TBL] [Abstract][Full Text] [Related]
4. Hemolytic uremic syndrome: differential diagnosis with the onset of inflammatory bowel diseases. Bianchi L; Gaiani F; Vincenzi F; Kayali S; Di Mario F; Leandro G; De' Angelis GL; Ruberto C Acta Biomed; 2018 Dec; 89(9-S):153-157. PubMed ID: 30561409 [TBL] [Abstract][Full Text] [Related]
5. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Kielstein JT; Beutel G; Fleig S; Steinhoff J; Meyer TN; Hafer C; Kuhlmann U; Bramstedt J; Panzer U; Vischedyk M; Busch V; Ries W; Mitzner S; Mees S; Stracke S; Nürnberger J; Gerke P; Wiesner M; Sucke B; Abu-Tair M; Kribben A; Klause N; Schindler R; Merkel F; Schnatter S; Dorresteijn EM; Samuelsson O; Brunkhorst R; Nephrol Dial Transplant; 2012 Oct; 27(10):3807-15. PubMed ID: 23114903 [TBL] [Abstract][Full Text] [Related]
6. Hemolytic uremic syndrome with simultaneous Shiga toxin producing Escherichia coli and complement abnormalities. McCoy N; Weaver DJ BMC Pediatr; 2014 Nov; 14():278. PubMed ID: 25373393 [TBL] [Abstract][Full Text] [Related]
7. Hemolytic uremic syndrome in children. Talarico V; Aloe M; Monzani A; Miniero R; Bona G Minerva Pediatr; 2016 Dec; 68(6):441-455. PubMed ID: 27768015 [TBL] [Abstract][Full Text] [Related]
8. Where are we with haemolytic uremic syndrome? Cavero T; Alonso M Med Clin (Barc); 2018 Oct; 151(8):329-335. PubMed ID: 29699703 [TBL] [Abstract][Full Text] [Related]
9. Pathophysiology and treatment of typical and atypical hemolytic uremic syndrome. Picard C; Burtey S; Bornet C; Curti C; Montana M; Vanelle P Pathol Biol (Paris); 2015 Jun; 63(3):136-43. PubMed ID: 25845294 [TBL] [Abstract][Full Text] [Related]
10. Eculizumab in severe Shiga-toxin-associated HUS. Lapeyraque AL; Malina M; Fremeaux-Bacchi V; Boppel T; Kirschfink M; Oualha M; Proulx F; Clermont MJ; Le Deist F; Niaudet P; Schaefer F N Engl J Med; 2011 Jun; 364(26):2561-3. PubMed ID: 21612462 [No Abstract] [Full Text] [Related]
11. [Hemolytic and uremic syndrome and related thrombotic microangiopathies: Treatment and prognosis]. Rafat C; Coppo P; Fakhouri F; Frémeaux-Bacchi V; Loirat C; Zuber J; Rondeau E Rev Med Interne; 2017 Dec; 38(12):833-839. PubMed ID: 28947259 [TBL] [Abstract][Full Text] [Related]
12. Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors. Le Clech A; Simon-Tillaux N; Provôt F; Delmas Y; Vieira-Martins P; Limou S; Halimi JM; Le Quintrec M; Lebourg L; Grangé S; Karras A; Ribes D; Jourde-Chiche N; Rondeau E; Frémeaux-Bacchi V; Fakhouri F Kidney Int; 2019 Jun; 95(6):1443-1452. PubMed ID: 30982675 [TBL] [Abstract][Full Text] [Related]
13. Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies. Keir LS; Marks SD; Kim JJ Drug Des Devel Ther; 2012; 6():195-208. PubMed ID: 22888220 [TBL] [Abstract][Full Text] [Related]
14. Renal and neurological involvement in typical Shiga toxin-associated HUS. Trachtman H; Austin C; Lewinski M; Stahl RA Nat Rev Nephrol; 2012 Nov; 8(11):658-69. PubMed ID: 22986362 [TBL] [Abstract][Full Text] [Related]
15. [The HUS epidemic in the summer of 2011 was severe. German and Swedish experiences of the EHEC outbreak]. Samuelsson O; Follin P; Rundgren M; Rylander C; Selga D; Ståhl A Lakartidningen; 2012 Jun 19-26; 109(25):1230-4. PubMed ID: 22838113 [No Abstract] [Full Text] [Related]
16. Posttransplant recurrence of atypical hemolytic uremic syndrome. Valoti E; Alberti M; Noris M J Nephrol; 2012; 25(6):911-7. PubMed ID: 22760880 [TBL] [Abstract][Full Text] [Related]
18. [Escherichia coli associated hemolytic and uremic syndrome: what lessons can be learned after the European epidemic of 2011?]. Lemaignen A; Ridel C; Hertig A; Rondeau E Nephrol Ther; 2013 Jun; 9(3):129-36. PubMed ID: 23266201 [TBL] [Abstract][Full Text] [Related]
19. [Treatment of typical hemolytic-uremic syndrome. Knowledge gained from analyses of the 2011 E. coli outbreak]. Menne J; Kielstein JT; Wenzel U; Stahl RA Internist (Berl); 2012 Dec; 53(12):1420-30. PubMed ID: 23179596 [TBL] [Abstract][Full Text] [Related]
20. Epidemiology, clinical presentation, and pathophysiology of atypical and recurrent hemolytic uremic syndrome. Zimmerhackl LB; Besbas N; Jungraithmayr T; van de Kar N; Karch H; Karpman D; Landau D; Loirat C; Proesmans W; Prüfer F; Rizzoni G; Taylor MC; Semin Thromb Hemost; 2006 Mar; 32(2):113-20. PubMed ID: 16575686 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]